R R

What Is Rozanolixizumab?

Rozanolixizumab-noli is a prescription monoclonal antibody marketed under the brand name Rystiggo. It is a neonatal Fc receptor blocker approved to treat generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Generalized myasthenia gravis is an autoimmune neuromuscular disease that causes fluctuating muscle weakness. Rozanolixizumab is administered through subcutaneous infusion by a healthcare professional in defined treatment cycles. It reduces circulating immunoglobulin G antibodies, including antibodies involved in the disease. Treatment can improve symptoms in eligible patients but does not cure the underlying autoimmune condition.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rozanolixizumab?

Rozanolixizumab-noli is a prescription monoclonal antibody marketed under the brand name Rystiggo. It is a neonatal Fc receptor blocker approved to treat generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Generalized myasthenia gravis is an autoimmune neuromuscular disease that causes fluctuating muscle weakness. Rozanolixizumab is administered through subcutaneous infusion by a healthcare professional in defined treatment cycles. It reduces circulating immunoglobulin G antibodies, including antibodies involved in the disease. Treatment can improve symptoms in eligible patients but does not cure the underlying autoimmune condition.

read more about rozanolixizumab ...

Copy this HTML:

Copy HTML Copied!

How Does Rozanolixizumab Work?

Rozanolixizumab binds to the neonatal Fc receptor, also called FcRn, which normally protects immunoglobulin G antibodies from degradation. Blocking this receptor increases the breakdown of circulating IgG antibodies, including autoantibodies that interfere with normal communication between nerves and muscles. In generalized myasthenia gravis, these autoantibodies can target the acetylcholine receptor or muscle-specific tyrosine kinase, impairing neuromuscular signaling. Lowering their levels can reduce disease-related weakness in eligible patients. Rozanolixizumab does not eliminate the underlying tendency to produce autoantibodies. Reduced IgG levels can also affect the body's defenses against infections and responses to certain vaccines.

What Condition Does Rozanolixizumab Treat?

Rozanolixizumab is approved for generalized myasthenia gravis in adults who are positive for anti-acetylcholine receptor antibodies or anti-muscle-specific tyrosine kinase antibodies. Generalized myasthenia gravis can affect muscles involved in eye movement, facial expression, swallowing, speech, breathing, and limb movement. Symptoms may fluctuate and worsen with activity. Rystiggo is not approved for every form of muscle weakness or for patients without the specified antibody findings. A neurologist confirms the diagnosis, evaluates the antibody test results, and assesses muscle strength and respiratory function before initiating treatment. Subsequent treatment cycles depend on the patient's clinical response.

How Is Rozanolixizumab Administered?

Rozanolixizumab is administered as a subcutaneous infusion once weekly for six weeks. The dose is based on body weight: 420 mg for patients weighing less than 50 kg, 560 mg for those weighing 50 kg to less than 100 kg, and 840 mg for patients weighing at least 100 kg. Infusions are administered by trained healthcare personnel using an appropriate infusion system. Additional six-week cycles are determined by clinical evaluation. The safety of starting a new cycle sooner than 63 days after the beginning of the previous cycle has not been established. Vaccination needs should be reviewed before each new treatment cycle, and live vaccines should be avoided during treatment.

What Are the Side Effects and Warnings of Rozanolixizumab?

Common adverse effects include headache, diarrhea, fever, and nausea. Serious risks include infections, hypersensitivity reactions, and aseptic meningitis, which can cause severe headache, fever, neck stiffness, nausea, and sensitivity to light. Because rozanolixizumab reduces circulating IgG, clinicians assess infection symptoms and vaccination needs before treatment. Infusions may need to be delayed in patients with active infections. The medication can also interfere with the effectiveness of certain treatments that depend on circulating IgG. Patients should report persistent fever, severe headache, neck stiffness, difficulty breathing, or signs of an allergic reaction. Significant neurological changes require prompt medical evaluation.

Common Questions About Rozanolixizumab

Is rozanolixizumab the same as Rystiggo?

Yes. Rystiggo is the brand name for rozanolixizumab-noli, a monoclonal antibody that blocks the neonatal Fc receptor.

Can rozanolixizumab treat myasthenia gravis?

Yes. It is approved for adults with generalized myasthenia gravis who are positive for anti-AChR or anti-MuSK antibodies.

How often is rozanolixizumab administered?

Rystiggo is administered by subcutaneous infusion once weekly for six weeks. Additional treatment cycles depend on clinical evaluation.

Can rozanolixizumab increase infection risk?

Yes. Rozanolixizumab lowers circulating IgG levels and can increase infection susceptibility. Patients should report signs of infection to their healthcare professional.

References

DailyMed - RYSTIGGO (rozanolixizumab-noli) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0eb8c2-c042-4954-b451-3baa77f5e6d1. Date Accessed November 4, 2026.

Rozanolixizumab in Generalized Myasthenia Gravis: Pooled Analysis of the Phase 3 MycarinG Study and Two Open-Label Extensions. PubMed. https://pubmed.ncbi.nlm.nih.gov/40033991/. Date Accessed November 4, 2026.

Rozanolixizumab-noli. MedlinePlus. https://medlineplus.gov/druginfo/meds/a623040.html. Date Accessed November 4, 2026.

Rystiggo. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/rystiggo. Date Accessed November 4, 2026.

Safety and Efficacy of Rozanolixizumab in Patients With Generalised Myasthenia Gravis (MycarinG): A Randomised, Double-Blind, Placebo-Controlled, Adaptive Phase 3 Study. The Lancet Neurology. https://pubmed.ncbi.nlm.nih.gov/37059507/. Date Accessed November 4, 2026.